Advertisement

Topics

Herpes simplex virus HSV 1 HSV 2 HHV 1 HHV 2 - Biotech, Pharma and Life Science Channel

01:12 EDT 22nd July 2018 | BioPortfolio

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders based on the site of infection: oral herpes with the visible symptoms of cold sores or fever blisters, genital herpes and other forms including ocular herpes (keratitis).

On an annual basis, without the use of antivirals or condoms, the transmission risk of HSV-2 from infected male to female is approximately 8-10%. Transmission risk from infected female to male is approximately 4-5% annually. Suppressive antiviral therapy reduces these risks by 50%. Antivirals also help prevent the development of symptomatic HSV in infection scenarios—meaning the infected partner will be seropositive but symptom free—by about 50%.

Vaccines for HSV are undergoing trials. Once developed, they may be used to help with prevention or minimize initial infections as well as treatment for existing infections. A laboratory at Harvard Medical School has developed dl5-29 (now known as ACAM-529), a replication-defective mutant virus that has proved successful both in preventing HSV-2/HSV-1 infections, and in combating the virus in already infected hosts, in animal models. This vaccine is now being researched and developed by Accambis, and is due to be applied as an Investigational New Drug in 2009. A private company called BioVex began Phase I clinical trials for ImmunoVEX, another proposed vaccine, in March 2010.

Antivirals may reduce asymptomatic shedding; it is believed asymptomatic genital HSV-2 viral shedding occurs on 20% of days per year in patients not undergoing antiviral treatment, versus 10% of days while on antiviral therapy. There is no method to eradicate herpes virus from the body, but antiviral medications can reduce the frequency, duration, and severity of outbreaks. Analgesics such as ibuprofen and acetaminophen can reduce pain and fever. Topical anesthetic treatments such as prilocaine, lidocaine, benzocaine or tetracaine can also relieve itching and pain. Topical microbicides which contain chemicals that directly inactivate the virus and block viral entry are being investigated.

Source; Wikipedia

Add the Herpes News Channel to your RSS reader;

News Articles [186 Associated News Articles listed on BioPortfolio]

Sage Bionetworks Launches the Agora Platform Making Curated Genomic Analysis of Alzheimer’s Disease Widely Available

Researchers to access list of novel targets for Alzheimer’s disease treatment Sage Bionetworks announces the launch of the Agora platform (agora.ampadportal.org) an i...

WuXi STA and Antengene Sign Development and Manufacturing Agreement

SHANGHAI, July 20, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) - a subsidiary of WuXi AppTec - and Antengene Corporation, a biopharmaceutical company, recently announced a ...

Turnstone Biologics Announces Key Appointments to Senior Leadership Team

Industry Veteran Jane Pritchett Henderson Named Chief Financial Officer Additional Leaders Hired to Advance Next-Generation Oncolytic Viral Immunotherapies ...

Quidel to Hold Second Quarter 2018 Financial Results Conference Call on August 7, 2018

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second quarter 20...

Contagion® Outbreak Monitor Provides Real-Time Updates to Clinicians on National Hepatitis A Outbreak

Affected states include Tennessee, West Virginia, Indiana, Michigan, Kentucky, Utah and California Contagion®, the nation’s leading digital and print publication tha...

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu

– Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonst...

Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver dise...

Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

– Venclexta represents a potential new way of treating AML, the most common type of aggressive leukemia in adults – Genentech, a member of the Roche Group (SIX: RO, ROG; O...

New Navy Policy Implements Full Adoption of Pathogen-Reduced Apheresis Platelets Collected at U.S. Navy Blood Donor Centers

Cerus Corporation (Nasdaq: CERS) announced today that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor C...

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene’s Virus-Based Immunotherapies TG6002 and TG1050 in Greater China

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares Deals give Tasly Biopharmaceuticals full control over Greater Chi...

Events [0 Results]

None

Companies [61 Associated Companies listed on BioPortfolio]

Hunterian Medicine LLC

Headquartered in Cambridge, Massachusetts, Hunterian Medicine LLC is a leading gene-editing company working to cure genetic diseases by correcting DNA mutations using its innovati...

Agilvax, Inc.

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, ...

Agilvax

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product,...

Seqirus

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in ...

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of s...

Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the development of rapid diagnostic solutions that can lead to improved patient o...

Nordtree

The 2nd International Zika Virus Conference is organized by Nordtree, an international specialist in public health and emergency planning events and disaster recovery confer...

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes...

Redox Pharmaceutical Corporation

Redox is a bio-pharmaceutical company that has developed chemical compounds shown in preclinical studies to be effective in the treatment and prevention of various viral and inflammatory diseases. Suc...

REPLICor Inc

REPLICor Inc. is a biopharmaceutical company developing novel broad-spectrum antiviral drugs. Its lead compound, REP 9, is active against 12 viral families including influenza, hepatitis B and C, HIV,...

Clinical Trials [2286 Associated Clinical Trials listed on BioPortfolio]

Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia

This study will evaluate two novel approaches to improve access to Hepatitis C virus (HCV) confirmatory viremia testing. Both approaches are "Harm reduction site-based (HRS)" because HCV v...

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple ascending doses of SH229 in patients with chronic hepatiti...

Safety, Reactogenicity and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A/H7N9 Inactivated Influenza Vaccines With or Without AS03 Adjuvant

This is a trial designed to assess the safety, reactogenicity and immunogenicity of one or two doses of monovalent inactivated split influenza 2013 and 2017 A/H7N9 virus vaccines administe...

Clinical Study of Structural and Functional Evaluation of the Visual Pathway

Sellar area tumors such as pituitary adenoma, craniopharyngioma and meningioma, etc, commonly lead to visual impairment symptoms. Patients suffer from a loss of visual acuity (VA) and visu...

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Patients with ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), have been shown to be at increased risk of developing certain infections, such as shingles from the Herpe...

Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

Hepatitis C virus (HCV) is a major cause of chronic liver disease. The World Health Organization has reported that 170 million people are chronically infected with HCV globally. The highes...

Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients

Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. In 2015, the prevalence of HCV RNA was found to be 7.0%.(1) The prevalence of HCV was studied in Rheumatoid arthri...

Study on Gut Microbiota in Chronic HBV Infected Patients

Hepatitis B Virus(HBV) infection is a common infectious disease affecting up to 2 billion people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary liver ca...

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

This study will assess the effect of treatment for hepatitis C virus (HCV) on cardiovascular disease risk. The study will enroll men and women who are infected with HCV and have underlying...

PubMed Articles [3981 Associated PubMed Articles listed on BioPortfolio]

Case of Microcephaly after Congenital Infection with Asian Lineage Zika Virus, Thailand.

We sequenced the virus genomes from 3 pregnant women in Thailand with Zika virus diagnoses. All had infections with the Asian lineage. The woman infected at gestational week 9, and not those infected ...

Cardiovascular disease burden among human immunodeficiency virus-infected individuals.

Human Immunodeficiency Virus (HIV) infection affects 36.7 million people worldwide, it accounted for 1.1 million deaths in 2015. The advent of combined antiretroviral therapy (cART) has been associate...

Long-term outcomes of varicella zoster virus infection-related myelitis in 10 immunocompetent patients.

To describe the clinical presentation and long-term disease outcomes of varicella zoster virus (VZV) infection-related myelitis (VZVM) in immunocompetent patients.

Isolation of Complete Equine Encephalitis Virus Genome from Human Swab Specimen, Peru.

While studying respiratory infections in Peru, we identified Venezuelan equine encephalitis virus (VEEV) in a nasopharyngeal swab, indicating that this alphavirus can be present in human respiratory s...

Identification of Peste des Petits Ruminants Virus, Georgia, 2016.

A phylogenetic analysis of samples taken from reported outbreaks of peste des petits ruminants virus (PPRV) in Georgia revealed a closer relationship to viruses from northern and eastern Africa than t...

Distinguishing Zika and Dengue Viruses through Simple Clinical Assessment, Singapore.

Dengue virus and Zika virus coexist in tropical regions in Asia where healthcare resources are limited; differentiating the 2 viruses is challenging. We showed in a case-control discovery cohort, and ...

Autochthonous Hepatitis E during Pregnancy, France.

Acute hepatitis E virus infections occurred during the third trimester in 2 pregnant women in France who sought treatment with nonspecific symptoms or asymptomatic elevation of liver enzymes. Infectio...

Unilateral Phrenic Nerve Palsy in Infants with Congenital Zika Syndrome.

Since the first identification of neonatal microcephaly cases associated with congenital Zika virus infection in Brazil in 2015, a distinctive constellation of clinical features of congenital Zika syn...

HIV Testing, Linkage to HIV Medical Care, and Interviews for Partner Services Among Black Men Who Have Sex with Men - Non-Health Care Facilities, 20 Southern U.S. Jurisdictions, 2016.

Identifying HIV-infected persons who are unaware of their human immunodeficiency virus (HIV) infection status, linking them to care, and reducing health disparities are important national HIV preventi...

Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016.

Worldwide, an estimated 257 million persons are living with chronic hepatitis B virus (HBV) infection (1). To achieve the World Health Organization (WHO) goals for elimination of HBV infection worldwi...

Videos

None available.

Medical and Biotech [MESH] Definitions

Trans-acting protein that combines with host factors to induce immediate early gene transcription in herpes simplex virus.

A cellular transcriptional coactivator that was originally identified by its requirement for the stable assembly IMMEDIATE-EARLY PROTEINS of the HERPES SIMPLEX VIRUS. It is a nuclear protein that is a transcriptional coactivator for a number of transcription factors including VP16 PROTEIN; GA-BINDING PROTEIN; EARLY GROWTH RESPONSE PROTEIN 2; and E2F4 TRANSCRIPTION FACTOR. It also interacts with and stabilizes HERPES SIMPLEX VIRUS PROTEIN VMW65 and helps regulate GENETIC TRANSCRIPTION of IMMEDIATE-EARLY GENES in HERPES SIMPLEX VIRUS.

Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.

A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)

Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.)

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

review and buy Herpes simplex virus HSV 1 HSV 2 HHV 1 HHV 2 market research data and corporate reports here

Channels Quicklinks